Mylan (NASDAQ:MYL) – Analysts at Leerink Swann issued their Q1 2018 EPS estimates for Mylan in a note issued to investors on Tuesday. Leerink Swann analyst A. Fadia anticipates that the company will earn $1.09 per share for the quarter. Leerink Swann currently has a “Market Perform” rating and a $44.00 price target on the stock. Leerink Swann also issued estimates for Mylan’s Q2 2018 earnings at $1.29 EPS, Q3 2018 earnings at $1.41 EPS, Q4 2018 earnings at $1.56 EPS and FY2022 earnings at $7.84 EPS.
Several other analysts have also issued reports on the company. Citigroup increased their target price on Mylan from $48.00 to $58.00 and gave the stock a “buy” rating in a research note on Thursday. Cantor Fitzgerald set a $41.00 price target on Mylan and gave the stock a “hold” rating in a research report on Tuesday, December 26th. BidaskClub raised Mylan from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 19th. Guggenheim assumed coverage on Mylan in a research report on Tuesday, December 12th. They set a “buy” rating and a $59.00 price target on the stock. Finally, UBS Group set a $46.00 price target on Mylan and gave the stock a “buy” rating in a research report on Monday, December 4th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $43.20.
Mylan (NASDAQ:MYL) last announced its quarterly earnings data on Monday, November 6th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.10). The business had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $3.09 billion. Mylan had a return on equity of 20.63% and a net margin of 7.28%. The firm’s revenue was down 2.3% on a year-over-year basis. During the same period in the prior year, the company posted $1.38 earnings per share.
Hedge funds have recently bought and sold shares of the company. Greenlight Capital Inc. boosted its stake in Mylan by 0.4% during the 3rd quarter. Greenlight Capital Inc. now owns 10,744,307 shares of the company’s stock valued at $337,048,000 after purchasing an additional 42,600 shares during the last quarter. Wealthsource Partners LLC boosted its stake in Mylan by 57.6% during the third quarter. Wealthsource Partners LLC now owns 14,705 shares of the company’s stock valued at $461,000 after buying an additional 5,375 shares in the last quarter. Americafirst Capital Management LLC bought a new position in Mylan during the third quarter valued at about $471,000. Cypress Capital Group boosted its stake in Mylan by 37.7% during the third quarter. Cypress Capital Group now owns 13,079 shares of the company’s stock valued at $410,000 after buying an additional 3,579 shares in the last quarter. Finally, California Public Employees Retirement System boosted its stake in Mylan by 4.2% during the third quarter. California Public Employees Retirement System now owns 1,129,978 shares of the company’s stock valued at $35,447,000 after buying an additional 45,822 shares in the last quarter. 74.90% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This report was first posted by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/01/04/mylan-myl-forecasted-to-post-q1-2018-earnings-of-1-09-per-share.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.